Regranion, LLC
Charleston, SC · Biotech · Private
HSP90 inhibitor small molecule therapeutic (RGRN-305) for atopic dermatitis and psoriasis
- Grants
- $2.0M
- 3 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 16
- 0 granted · 16 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · A Novel Topical HSP90 Inhibitor (CTXT-102) in the Treatment of Mild to Moderate Plaque Psoriasis | $1,225,570 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Topical HSP90 Inhibitor (CTXT-102) in the Treatment of Mild to Moderate Plaque Psoriasis | $571,536 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel small molecule HSP90 inhibitor for the management of atopic dermatitis | $252,131 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1906 | MBF THERAPEUTICS, INC. | — | $2.0M |
| 1907 | GRANNUS THERAPEUTICS, INC. | — | $1.8M |
| 1908 | Mitera Biosciences Inc. | — | $1.7M |
| 1909 | Regranion, LLC | — | — |
| 1910 | Yobee Care, Inc. | — | $1.4M |
| 1911 | Wise Trading Technologies, Inc. | — | $85K |
| 1912 | GRO BIOSCIENCES INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods and Compositions for Treating Hidradenitis Suppurativaapplication
- Methods And Compositions For Treating Discoid Lupus Erythematosus, Systemic Lupus Erythematosus, And Subacute Cutaneous Lupus Erythematosusapplication
- Methods And Compositions For Treating Behçet's Diseaseapplication
- Methods And Compositions For Treating Bullous Pemphigoidapplication
- Methods And Compositions For Treating Atopic Dermatitisapplication
- Methods And Compositions For Treating Bullous Pemphigoidapplication
- Methods And Compositions For Treating Behçet's Diseaseapplication
- Methods And Compositions For Treating Discoid Lupus Erythematosus And Subacute Cutaneous Lupus Erythematosusapplication
- Methods And Compositions For Treating Bullous Pemphigoidapplication
- Methods And Compositions For Treating Behçet's Diseaseapplication
- Methods And Compositions For Treating Discoid Lupus Erythematosus And Subacute Cutaneous Lupus Erythematosusapplication
- Methods And Compositions For Treating Hidradenitis Suppurativaapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.